Institution
University of Adelaide
Education•Adelaide, South Australia, Australia•
About: University of Adelaide is a education organization based out in Adelaide, South Australia, Australia. It is known for research contribution in the topics: Population & Pregnancy. The organization has 27251 authors who have published 79167 publications receiving 2671128 citations. The organization is also known as: The University of Adelaide & Adelaide University.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The complex molecular interactions of the ligands and receptors of the IGF system underlie all the biological actions mentioned above and will be the focus of this review.
407 citations
••
Dalhousie University1, Charité2, National Institutes of Health3, University of Geneva4, Karolinska Institutet5, State University of Campinas6, University of Adelaide7, University of Paris8, Medical University of Graz9, Mayo Clinic10, Academia Sinica11, University of Bonn12, University of Cagliari13, Johns Hopkins University14, French Institute of Health and Medical Research15, Ludwig Maximilian University of Munich16, Neuroscience Research Australia17, University of Toronto18, University of Göttingen19, Osaka University20, University of California, San Diego21, United States Department of Veterans Affairs22, University of Würzburg23, National Taiwan University24, Hokkaido University25, University of Antioquia26, University of Naples Federico II27, University of New South Wales28, Nagoya University29, Fujita Health University30, Harvard University31, Dresden University of Technology32, University of Iowa33, Université de Montréal34, University of Queensland35, Heidelberg University36
TL;DR: The key phenotypic measures of the “Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder” scale currently used in the Consortium on lithium Genetics (ConLiGen) study are reported.
Abstract: OBJECTIVE: The assessment of response to lithium maintenance treatment in bipolar disorder (BD) is complicated by variable length of treatment, unpredictable clinical course, and often inconsistent compliance. Prospective and retrospective methods of assessment of lithium response have been proposed in the literature. In this study we report the key phenotypic measures of the "Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder" scale currently used in the Consortium on Lithium Genetics (ConLiGen) study. MATERIALS AND METHODS: Twenty-nine ConLiGen sites took part in a two-stage case-vignette rating procedure to examine inter-rater agreement [Kappa (κ)] and reliability [intra-class correlation coefficient (ICC)] of lithium response. Annotated first-round vignettes and rating guidelines were circulated to expert research clinicians for training purposes between the two stages. Further, we analyzed the distributional properties of the treatment response scores available for 1,308 patients using mixture modeling. RESULTS: Substantial and moderate agreement was shown across sites in the first and second sets of vignettes (κ = 0.66 and κ = 0.54, respectively), without significant improvement from training. However, definition of response using the A score as a quantitative trait and selecting cases with B criteria of 4 or less showed an improvement between the two stages (ICC1 = 0.71 and ICC2 = 0.75, respectively). Mixture modeling of score distribution indicated three subpopulations (full responders, partial responders, non responders). CONCLUSIONS: We identified two definitions of lithium response, one dichotomous and the other continuous, with moderate to substantial inter-rater agreement and reliability. Accurate phenotypic measurement of lithium response is crucial for the ongoing ConLiGen pharmacogenomic study.
407 citations
••
Commonwealth Scientific and Industrial Research Organisation1, University of Calgary2, Swinburne University of Technology3, York University4, Durham University5, University of Sydney6, University of Colorado Boulder7, University of Tasmania8, University of California, Berkeley9, University of Adelaide10, Laval University11, McGill University12, Herzberg Institute of Astrophysics13, California Institute of Technology14, La Trobe University15, University of Toronto16, University of British Columbia17, University of Western Australia18, Curtin University19
TL;DR: The Australian SKA Pathfinder (ASKAP) as mentioned in this paper is aimed squarely in this frequency range, and achieves instantaneous wide-area imaging through the development and deployment of phase-array feed systems on parabolic reflectors.
Abstract: The future of cm and m-wave astronomy lies with the Square Kilometre Array (SKA), a telescope under development by a consortium of 17 countries. The SKA will be 50 times more sensitive than any existing radio facility. A majority of the key science for the SKA will be addressed through large-area imaging of the Universe at frequencies from 300 MHz to a few GHz. The Australian SKA Pathfinder (ASKAP) is aimed squarely in this frequency range, and achieves instantaneous wide-area imaging through the development and deployment of phase-array feed systems on parabolic reflectors. This large field-of-view makes ASKAP an unprecedented synoptic telescope poised to achieve substantial advances in SKA key science. The central core of ASKAP will be located at the Murchison Radio Observatory in inland Western Australia, one of the most radio-quiet locations on the Earth and one of the sites selected by the international community as a potential location for the SKA. Following an introductory description of ASKAP, this document contains 7 chapters describing specific science programmes for ASKAP. In summary, the goals of these programmes are as follows: The combination of location, technological innovation and scientific program will ensure that ASKAP will be a world-leading radio astronomy facility, closely aligned with the scientific and technical direction of the SKA. A brief summary chapter emphasizes the point, and considers discovery space.
406 citations
••
TL;DR: Reported ELS is associated with smaller ACC and caudate volumes, but not the hippocampal or amygdala volumes, which may reflect the influence of early stress and traumatic events on the developing brain.
406 citations
••
TL;DR: The consensus guideline methodology is described, the evidence-based recommendations provided to the World Health Organisation (WHO) for their consideration in the development of global guidance are summarised and a narrative review on the management of anovulatory infertility in women with polycystic ovary syndrome is presented.
Abstract: BACKGROUND: Here we describe the consensus guideline methodology, summarise the evidence-based recommendations we provided to the World Health Organisation (WHO) for their consideration in the development of global guidance and present a narrative review on the management of anovulatory infertility in women with polycystic ovary syndrome (PCOS). OBJECTIVE AND RATIONALE: The aim of this paper was to present an evidence base for the management of anovulatory PCOS. SEARCH METHODS: The evidence to support providing recommendations involved a collaborative process for: (i) identification of priority questions and critical outcomes, (ii) retrieval of up-to-date evidence and exiting guidelines, (iii) assessment and synthesis of the evidence and (iv) the formulation of draft recommendations to be used for reaching consensus with a wide range of global stakeholders. For each draft recommendation, the methodologist evaluated the quality of the supporting evidence that was then graded as very low, low, moderate or high for consideration during consensus. OUTCOMES: Evidence was synthesized and we made recommendations across the definition of PCOS including hyperandrogenism, menstrual cycle regulation and ovarian assessment. Metabolic features and the impact of ethnicity were covered. Management includes lifestyle changes, bariatric surgery, pharmacotherapy (including clomiphene citrate (CC), aromatase inhibitors, metformin and gonadotropins), as well as laparoscopic surgery. In-vitro fertilization (IVF) was considered as were the risks of ovulation induction and of pregnancy in PCOS. Approximately 80% of women who suffer from anovulatory infertility have PCOS. Lifestyle intervention is recommended first in women who are obese largely on the basis of general health benefits. Bariatric surgery can be considered where the body mass index (BMI) is ≥35 kg/m(2) and lifestyle therapy has failed. Carefully conducted and monitored pharmacological ovulation induction can achieve good cumulative pregnancy rates and multiple pregnancy rates can be minimized with adherence to recommended protocols. CC should be first-line pharmacotherapy for ovulation induction and letrozole can also be used as first-line therapy. Metformin alone has limited benefits in improving live birth rates. Gonadotropins and laparoscopic surgery can be used as second-line treatment. There is no clear evidence for efficacy of acupuncture or herbal mixtures in women with PCOS. For women with PCOS who fail lifestyle and ovulation induction therapy or have additional infertility factors, IVF can be used with the safer gonadotropin releasing hormone (GnRH) antagonist protocol. If a GnRH-agonist protocol is used, metformin as an adjunct may reduce the risk of ovarian hyperstimulation syndrome. Patients should be informed of the potential side effects of ovulation induction agents and of IVF on the foetus, and of the risks of multiple pregnancy. Increased risks for the mother during pregnancy and for the child, including the exacerbating impact of obesity on adverse outcomes, should also be discussed. WIDER IMPLICATIONS: This guidance generation and evidence-synthesis analysis has been conducted in a manner to be considered for global applicability for the safe administration of ovulation induction for anovulatory women with PCOS.
405 citations
Authors
Showing all 27579 results
Name | H-index | Papers | Citations |
---|---|---|---|
Martin White | 196 | 2038 | 232387 |
Nicholas G. Martin | 192 | 1770 | 161952 |
David W. Johnson | 160 | 2714 | 140778 |
Nicholas J. Talley | 158 | 1571 | 90197 |
Mark E. Cooper | 158 | 1463 | 124887 |
Xiang Zhang | 154 | 1733 | 117576 |
John E. Morley | 154 | 1377 | 97021 |
Howard I. Scher | 151 | 944 | 101737 |
Christopher M. Dobson | 150 | 1008 | 105475 |
A. Artamonov | 150 | 1858 | 119791 |
Timothy P. Hughes | 145 | 831 | 91357 |
Christopher Hill | 144 | 1562 | 128098 |
Shi-Zhang Qiao | 142 | 523 | 80888 |
Paul Jackson | 141 | 1372 | 93464 |
H. A. Neal | 141 | 1903 | 115480 |